Autres langues Aldeyra Therapeutics, Inc.

Actions

ALDX

US01438T1060

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 29/04/2024			Varia. 5j.	Varia. 1 janv.
4,05 ^USD	+3,05 %		+3,05 %	+15,38 %

25/04	Transcript : Aldeyra Therapeutics, Inc. - Special Call
03/04	ALDEYRA THERAPEUTICS, INC. : Oppenheimer relève à l'achat	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day	25/04
Aldeyra Therapeutics to Host Research and Development Day on April 25, 2024	19/04
Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024	18/04
North American Morning Briefing : Focus Turns to -2-	04/04
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease	28/03
Aldeyra Therapeutics, Inc. Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease	28/03
Aldeyra Therapeutics Insider Sold Shares Worth $580,760, According to a Recent SEC Filing	13/03
Aldeyra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference	06/02
Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of Rasp Platform in Systemic and Retinal Inflammatory Diseases	04/01
Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases	04/01
Aldeyra Therapeutics, Inc. and Abbvie to Enter into the Co-Development, Co-Commercialization and License Agreement	21/12
Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis	20/12
Aldeyra Therapeutics Shares Jump as Skin Drug Shows Significant Improvement in Clinical Trial	19/12
Aldeyra Therapeutics' skin disease drug succeeds in mid-stage study	19/12
Aldeyra Therapeutics' eczema drug succeeds in mid-stage study	19/12
Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis	19/12
Aldeyra Therapeutics, Inc. Announces Positive Top-Line Results from A Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis	19/12
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis	18/12
Aldeyra Therapeutics, Inc.(NasdaqCM:ALDX) dropped from S&P Biotechnology Select Industry Index	18/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Aldeyra Therapeutics, Inc.

Actions

ALDX

US01438T1060

Autres langues

Filtres